Andrew Warwick Hamer Acquires 18,900 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Andrew Warwick Hamer bought 18,900 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was bought at an average price of C$1.88 per share, with a total value of C$35,606.69.

Cardiol Therapeutics Trading Up 0.6 %

TSE CRDL opened at C$1.81 on Thursday. The company has a current ratio of 2.39, a quick ratio of 6.84 and a debt-to-equity ratio of 1.07. Cardiol Therapeutics Inc. has a 1-year low of C$1.09 and a 1-year high of C$4.26. The firm’s fifty day simple moving average is C$2.32 and its 200-day simple moving average is C$2.65. The company has a market capitalization of C$126.48 million, a PE ratio of -4.11 and a beta of 0.70.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.